Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies
Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies
The City of Baltimore, led by Mayor Brandon M. Scott, reached an $80 million settlement with Teva Pharmaceuticals Industries Ltd (NYSE:TEVA) to resolve claims against the company for its role in the city's opioid epidemic.
由市長布蘭登·斯科特領導的巴爾的摩市與梯瓦製藥工業有限公司（紐約證券交易所代碼：TEVA）達成了8000萬美元的和解協議，以解決針對該公司在該市阿片類藥物流行中的作用的索賠。
Under the agreement, Teva will pay an initial $35 million by the end of 2024, with the remaining amount due by July 1, 2025.
根據該協議，梯瓦將在2024年底之前初步支付3500萬美元，剩餘款項將在2025年7月1日之前到期。
Also Read: JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability.
另請閱讀：摩根大通對Teva和Organon表現出最大的興趣，因爲特種製藥行業表現出穩定的跡象。
The settlement is part of Baltimore's broader litigation strategy against opioid manufacturers and distributors.
該和解協議是巴爾的摩針對阿片類藥物製造商和分銷商的更廣泛訴訟戰略的一部分。
Previous settlements with AbbVie Inc's (NYSE:ABBV) Allergan, CVS Health Corp (NYSE:CVS), and Cardinal Health Inc (NYSE:CAH) have brought in $322.5 million in total recoveries.
先前與艾伯維公司（紐約證券交易所代碼：ABBV）Allergan、CVS Health Corp（紐約證券交易所代碼：CVS）和Cardinal Health Inc（紐約證券交易所代碼：CAH）的和解共帶來了3.225億美元的總回收額。
The ongoing legal battle will proceed to trial on Sept. 16 against the remaining defendants, who were responsible for more than half of the opioids distributed in Baltimore.
正在進行的法律鬥爭將於9月16日進入審判，其餘被告應對在巴爾的摩分發的阿片類藥物的一半以上負責。
Mayor Scott emphasized the city's decision to opt out of the national Teva settlement, which would have yielded only $11 million over 13 years. Instead, the new agreement brings in more than seven times that amount in under a year.
斯科特市長強調了該市選擇退出全國Teva和解協議的決定，該協議在13年內只能產生1100萬美元的收益。相反，新協議在不到一年的時間內帶來的收入是該金額的七倍多。
Baltimore secured more than three times the funds it would have received from global settlements.
巴爾的摩獲得的資金是其本應從全球結算中獲得的資金的三倍多。
Baltimore will dedicate $5 million to education and outreach about the 988 crisis helpline, $3 million to the Penn North Recovery Center and $2 million to BMore Power.
巴爾的摩將撥款500萬美元用於有關988危機求助熱線的教育和宣傳，300萬美元用於賓夕法尼亞北部康復中心，200萬美元用於bMore Power。
Additional funds will be administered following the framework detailed in the executive order to address the ongoing epidemic.
將按照行政命令中詳述的框架管理額外資金，以應對持續的疫情。
In July, Teva announced topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17.
7月，梯瓦公佈了其3期SPACE研究的主要結果，該研究評估了Ajovy（fremanezumab）預防6-17歲兒童和青少年患者發作性偏頭痛的療效。
The trial met its primary endpoint with Ajovy achieving a statistically significant superior efficacy over 12 weeks of treatment compared to placebo.
該試驗達到了其主要終點，與安慰劑相比，Ajovy在12周的治療中取得了統計學上顯著的卓越療效。
TEVA Price Action: Teva stock is down 1.43% at $17.55 at last check Tuesday.
TEVA價格走勢：在週二的最後一次檢查中，梯瓦股價下跌1.43％，至17.55美元。
- Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety.
- Viridian Therapeutics披露了來自實驗性甲狀腺眼病候選物的 「令人興奮的」 數據，稱該數據在療效和安全性方面達到了很高的標準。
Photo: Ralf Liebhold via Shutterstock
照片：來自 Shutterstock 的 Ralf Liebhold
譯文內容由第三人軟體翻譯。